Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Product Type & Technology The global multiplex assays market will witness a robust CAGR of 7.53%, valued at $3.36 billion in 2021, expected to appreciate and reach $6.47 billion by 2030, confirms Strategic Market Research. The multiplex assay is one of the most crucial derivatives of an ELISA, using beads to bind the "capture" antibody. The "capture" antibody helps bind and retain the sample analyte. Key Industry Drivers - Rising numbers of NCDs and Infectious Diseases and the Increase in the Use of Multiplex Assays in Companion Diagnostics The continuous rising prevalence of chronic (non-communicable) and infectious diseases across the globe is one of the major factors that augment the overall market growth throughout the estimated time frame. According to the World Health Organization, chronic/ non-communicable diseases (NCD) kill 41 Mn people each year, which is equivalent to 71% of all the deaths occurring globally. Each year, more than 15 million people between the ages of (30 to 69) die due to an NCD. Approximately 85% of these "premature" deaths occur in middle and low-income countries. CVDs (cardiovascular diseases) are the most common type of NCD, which leads to the highest number of deaths worldwide (i.e., 17.9 Mn people annually), followed by cancers (9.3 Mn), respiratory diseases (4.1 Mn), and diabetes (1.5 Mn). Also, as per the National Institutes of Health, 5 types of infectious diseases are ranked among the top ten killer diseases worldwide, namely lower respiratory infections diseases (3.4 Mn deaths), HIV/AIDS (2.6 Mn deaths), diarrheal diseases (1.8 Mn deaths), tuberculosis (1.6 Mn deaths), and malaria (1.1 Mn deaths). Apart from the increase of chronic and infectious diseases, the rising awareness of disease diagnosis and the rising prevalence of multiplex assays in companion diagnostics, the requirement for effective analytical platforms in R&D is propelling the overall market growth significantly. Further, the rise in usage of several advanced technologies and processes like multiplex bead array assays, map assay, Invitrogen Luminex, cytokine immunoassay, multiplex Merck, RNA scope v2, magpix assay, msd cytokine multiplex, magpix cytokine assay, rnascope multiplex fluorescent v2 assay, multiplex assays, xmap luminex, multiplex assays ELISA, etc. are fuelling the growth of the market worldwide. Restraints - Expensive Equipment & Stringent Regulations The higher equipment costs are one of the major factors restraining the overall multiplex assays market growth, as it constantly challenges the manufacturers and researchers to perform multiplex assay testing at an affordable cost. Also, the standards for Quality control (Q.C.) of the multiplex assays are more stringent than the single-plex assays, thereby obstructing the overall market growth. Opportunities - The Increase in the Need for Automated Systems and the Rising Prevalence of the Biomarkers in Protein and Molecular Diagnostics in the Asia-Pacific Region Multiple biomarker analysis has a major application in the area of autoimmune diseases, cancer, and neurodegenerative diseases. With the discovery of many biomarkers, there is a higher probability of developing new diagnostic tests in the Asia-Pacific region, which is expected to create ample growth opportunities in the future. Also, the latest development in the Technology of an automated multiplex assay instrument is expected to boost the overall market growth, which will help the market grow exponentially in the future. Market Analysis Of Different Segments Covered in the Report Based on Product and Service Instruments Consumables Software and Services Based on Type Nucleic Acid Multiplex Assays Planar Nucleic Acid Assays Bead-Based Nucleic Acid Assays Others Protein Multiplex Assays Planar Protein Assays Bead-Based Protein Assays Others Cell-Based Multiplex Assays Based on Technology Fluorescence Detection Luminescence Flow Cytometry Multiplex Real-Time PCR Others Based on Applications Research & Development Biomarker Discovery & Validation Drug Discovery & Development Clinical Diagnostics Cancer Cardiovascular Diseases Infectious Diseases Autoimmune Diseases Metabolism & Endocrinology Disorders Nervous System Disorders Others Based on End-User Hospitals & Research Institutes Pharmaceutical & Biotechnology Companies Reference Laboratories Others Regional Coverage Analysis North America United States Mexico Canada Rest of North America Europe Switzerland Russia France Germany U.K Finland Turkey Netherlands Belgium Spain Italy Rest of Europe Asia Pacific China India Indonesia South Korea Thailand Japan Singapore Malaysia Philippines Australia New Zealand Rest of APAC LAMEA Brazil Saudi Arabia Uruguay Argentina Rest of LAMEA Based on Product & Service, the 'Consumables' segment held the highest share of almost 44.27% of the entire multiplex assays market in 2020. It also held the fastest growth rate with a decent CAGR throughout the forecasted period. The vital factors like the higher usage of reagents for facilitating research applications on consumables and the increase in the number of recurring purchases of assays worldwide are fuelling this segment's overall growth. Based on Type, the 'Protein Multiplex Assays' segment dominated the overall market with a steady CAGR during the estimated period owing to the sheer focus on proteomics studies for clinical diagnostics and biomarker research. According to IBISWorld, in 2021, there will be about 28,393 Diagnostic & Medical Laboratory businesses in the United States, with an increase of nearly 1.5 percent from 2020. Based on Technology, the 'Flow Cytometry segment held the largest share (approximately 37.28%) of the entire market in 2020, with a decent CAGR of 8.27%. The largest share of this segment can primarily be attributed to the wide range of flow cytometry applications in the measurement and detection of RNA, protein expression, and cell viability & toxicity, along with the identification and characterization of various cell types. Based on Applications, the 'Research & Development segment dominated the market in 2020 due to the increase of funds by the worldwide governments for the broad applications of multiplex assay technologies in R&D functions. The R&D outsourcing services market is accelerating at a CAGR of 7.93%, which in turn is propelling the overall growth of this segment. Based on End Users, the 'Pharmaceutical & Biotechnology Companies' segment accounted for the highest market share in 2020. Factors such as the rising focus of biotechnological companies on developing monoclonal and biosimilars antibodies and the increase in the number of adoptions of multiplex assays in the field of drug discovery by pharmaceuticals are significantly driving the overall growth of this segment. Based on Regions, North America held the largest regional market share with a CAGR of 8.93% in 2020, followed by Europe. The highest share of the North American region can primarily be attributed to the presence of leading pharmaceutical and biotechnology companies, established pharmaceutical industries, and increased R&D expenditures by the government. Multiplex assays market is significantly higher in the United States than in any other country. In addition, the government spending on the clinical services laboratory has increased by approximately 5.23% between 2010 to 2020, which has highly boosted the market in the United States. Global Multiplex Assays Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the worldwide market environment. The comparison is performed based on overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites and facilities, market potential, etc. Luminex Corporation Illumina Inc Bio-Rad Laboratories, Inc. Qiagen N.V. Thermo Fisher Scientific Inc Abcam plc Merck KGaA Agilent Technologies, Inc. Becton, Dickinson, and Company Meso Scale Diagnostics Randox Laboratories Quanterix Bio-Techne Corporation Olink DiaSorin S.p.A. Seegene Promega Corporation Siemens Healthineers PerkinElmer Inc. Shimadzu Biotech Antigenix America, Inc. Enzo Life Sciences, Inc. Boster Biological Technology AYOXXA Biosystems GmbH Cayman Chemical Company Multiplex Assays Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 3.36 billion The revenue forecast in 2030 USD 6.47 billion Growth rate CAGR of approximately 7.53% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Based on Product & Service, Type, Technology, Applications, End-User, and Regions. Based on Product & Service Instruments, Consumables, Software and Services Based on Type Nucleic Acid Multiplex Assays (Planar Nucleic Acid Assays, Bead-Based Nucleic Acid Assays, Others), Protein Multiplex Assays (Planar Protein Assays, Bead-Based Protein Assays, Others), Cell-Based Multiplex Assays Based on Technology Fluorescence Detection, Luminescence, Flow Cytometry, Multiplex Real-Time PCR, Others Based on Applications Research & Development (Biomarker Discovery & Validation, Drug Discovery & Development), Clinical Diagnostics (Cancer, Cardiovascular Diseases, Infectious Diseases, Autoimmune Diseases, Metabolism & Endocrinology Disorders, Nervous System Disorders, Others) Based on End-User Hospitals & Research Institutes, Pharmaceutical & Biotechnology Companies, Reference Laboratories, Others Based on Regions North America, Europe, Asia Pacific, LAMEA Country Scope United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa Company Usability Profiles Luminex Corporation, Illumina Inc, Bio-Rad Laboratories, Inc, Qiagen N.V, Thermo Fisher Scientific Inc, Abcam plc, Merck KGaA, Agilent Technologies, Inc, Becton, Dickinson, and Company, Meso Scale Diagnostics, Randox Laboratories, Quanterix, Bio-Techne Corporation, Olink, DiaSorin S.p.A., Seegene, Promega Corporation, Siemens Healthineers, PerkinElmer Inc., Shimadzu Biotech, Antigenix America, Inc., Enzo Life Sciences, Inc., Boster Biological Technology, AYOXXA Biosystems GmbH, Cayman Chemical Company Recent Developments On August 2021, Becton, Dickinson, and Company launched its new automated high-throughput diagnostic BD COR System. The system uses sample management software algorithms and robotics technology to set up a new standard in molecular testing automation for infectious diseases in core laboratories in the United States. On April 2021, Illumina successfully acquired GRAIL; a world-renowned healthcare company focused on providing early life-saving detection of multiple types of cancers. However, Illumina will hold GRAIL as a separate company during the European Commission's ongoing regulatory review. On February 2021, Thermo Fisher Scientific succeeded in acquiring Mesa Biotech, a privately held POC (point-of-care) molecular diagnostic company. By combining Thermo Fisher's excellence in operations, existing sales and distribution channels with Mesa's innovative platform, and direct access to the raw materials, rapid scaling of manufacturing volume can be performed easily. The List of Key Products that Global Market Leaders Develop PRODUCT NAME FUNCTION COMPANY Invitrogen Instant ELISA kits The instant ELISA Kits have ready-to-use plates that contain all the necessary assay components like lyophilized detection antibody, capture antibody, sample diluent, and streptavidin-HRP. These plates help in the reduction of pipetting time and also enable a simple one-wash type of protocol. Thermo Fisher Scientific Inc Human IL-6 ELISA Kit II It is designed in such a brilliant way that it can successfully measure the total amount of targeted bound between a matched pair of antibodies. Becton, Dickinson, and Company SIMOA Acts as an accelerator or catalyst in the Laboratory for Protein biomarker testing processes. Quanterix ADVIA Centaur XPT Immunoassay System It is one of the highest-throughput systems that can ever be available. It delivers the perfect results that the clinicians depend upon for better patient care and accurate diagnoses. Siemens Healthineers Frequently Asked Question About This Report How big is the multiplex assays market size? The global multiplex assays market size was $3.36 billion in 2021 and is predicted to reach $6.47 billion by 2030, with a CAGR of 7.53%. Which is the most dominant type of product and service in the market? Based on Product and Service, the Consumables segment held the highest share of almost 44.27% of the entire market in 2020. Which is the most leading segment among the End-User of the market Based on End User, the Pharmaceutical & Biotechnology Companies segment accounted for the highest market share in 2020. What is the multiplex assays market growth? The global multiplex assays market is expected to grow at a compound annual growth rate (CAGR) of 7.53% from 2021 to 2030 to reach USD 6.47 billion by 2030. Who are the essential players of the market? The most vital players of the market are Luminex Corporation, Illumina Inc, Bio-Rad Laboratories, Inc, Qiagen N.V., Thermo Fisher Scientific Inc, Abcam plc, Merck KGaA, Agilent Technologies, Inc, Becton, Dickinson and Company, Meso Scale Diagnostics, Randox Laboratories, Quanterix, Bio-Techne Corporation, Olink, DiaSorin S.p.A., Seegene, Promega Corporation, Siemens Healthineers, PerkinElmer Inc, Shimadzu Biotech, Antigenix America, Inc, Enzo Life Sciences, Inc, Boster Biological Technology, AYOXXA Biosystems GmbH, and Cayman Chemical Company. Sources https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases https://news.bd.com/2021-08-25-BD-Launches-Fully-Automated-High-Throughput-Molecular-Diagnostic-Platform-for-U-S-Laboratories 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Multiplex Assays Market 4.2.1 Global market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global market, by region, 2021 - 2030 (USD Million) 4.4 By Product and Service Analysis 4.4.1 Global market, By Product and Service, 2021 - 2030 (USD Million) 4.5 By Technology Business Analysis 4.5.1 Global market, By Technology, 2021 - 2030 (USD Million) 4.6 By Type Analysis 4.6.1 Global market, By Type, 2021 - 2030 (USD Million) 4.7 By End-User Business Analysis 4.7.1 Global market, By End-User, 2021 - 2030 (USD Million) 4.8 Application Business Analysis 4.8.1 Global market, By Application, 2021 - 2030 (USD Million) 4.9 Value Chain Analysis 4.10 Market Variable Analysis 4.10.1 Market Drivers Analysis 4.10.2 Market Restraints Analysis 4.11 Business Environment Analysis Tool 4.11.1 market PEST analysis 4.11.2 market Porter’s analysis 4.12 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2021) 5.11.2. Trends in Technology (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product and Service Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Instruments 7.3.1. Instruments market, 2021 - 2030 (USD Million) 7.4. Consumables 7.4.1. Consumables market, 2021 - 2030 (USD Million) 7.5 Software and Services 7.5.1 Software and Services market, 2021 - 2030 (USD Million) 8. Global Market: By Technology Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Fluorescence Detection 8.3.1. Fluorescence Detection market, 2021 - 2030 (USD Million) 8.4. Luminescence 8.4.1. Luminescence market, 2021 - 2030 (USD Million) 8.5 Flow Cytometry 8.5.1 Flow Cytometry market, 2021 - 2030 (USD Million) 8.6 Multiplex Real-Time PCR 8.6.1 Multiplex Real-Time PCR market, 2021 - 2030 (USD Million) 8.7 Others 8.7.1 Others market, 2021 - 2030 (USD Million) 9. Global Market: By Type Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Nucleic Acid 9.3.1. Nucleic Acid market, 2021 - 2030 (USD Million) 9.3.1.1 Planar Nucleic Acid Assays market, 2021 - 2030 (USD Million) 9.3.1.2 Bead-Based Nucleic Acid Assays market, 2021 - 2030 (USD Million) 9.3.1.3 Others market, 2021 - 2030 (USD Million) 9.4. Protein 9.4.1. Protein market, 2021 - 2030 (USD Million) 9.4.1.1 Planar Protein Assays market, 2021 - 2030 (USD Million) 9.4.1.2 Bead-Based Protein Assays market, 2021 - 2030 (USD Million) 9.4.1.3 Others market, 2021 - 2030 (USD Million) 9.5 Cell-Based 9.5.1 Cell-Based market, 2021 - 2030 (USD Million) 10. Global Market: By End-User Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals & Research Institutes 10.3.1. Hospitals & Research Institutes Market, 2021 - 2030 (USD Million) 10.4. Pharmaceutical & Biotechnology Companies 10.4.1. Pharmaceutical & Biotechnology Companies market, 2021 - 2030 (USD Million) 10.5 Reference Laboratories 10.5.1 Reference Laboratories market, 2021 - 2030 (USD Million) 10.6 Others 10.6.1 Others market, 2021 - 2030 (USD Million) 11. Global Market: By Application Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Research & Development 11.3.1. Research & Development market, 2021 - 2030 (USD Million) 11.3.1.1 Biomarker Discovery & Validation market, 2021 - 2030 (USD Million) 11.3.1.1 Drug Discovery & Development market, 2021 - 2030 (USD Million) 11.4. Clinical Diagnostics 11.4.1. Clinical Diagnostics market, 2021 - 2030 (USD Million) 11.4.1.1 Cancer market, 2021 - 2030 (USD Million) 11.4.1.2 Cardiovascular Diseases market, 2021 - 2030 (USD Million) 11.4.1.3 Infectious Diseases market, 2021 - 2030 (USD Million) 11.4.1.4 Autoimmune Diseases market, 2021 - 2030 (USD Million) 11.4.1.5 Metabolism & Endocrinology Disorders market, 2021 - 2030 (USD Million) 11.4.1.6 Nervous System Disorders market, 2021 - 2030 (USD Million) 11.4.1.7 Others market, 2021 - 2030 (USD Million) 12. Global Market: Regional Outlook 12.1 North America 12.1.1. North America market, By End-User, 2021 - 2030 (USD Million) 12.1.4. North America market, By Application, 2021 - 2030 (USD Million) 12.1.5. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By End-User, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By End-User, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Region, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by Applications, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By End-User, 2021 - 2030 (USD Million) 12.2.2. Europe market, by By Application, 2021 - 2030 (USD Million) 12.2.5. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By End-User, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Applications, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by Region, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By End-User, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by Region, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By End-User, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Region, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by Application, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By End-User, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Region, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by Application, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By End-User, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By End-User, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Region, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by Application, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By End-User, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Region, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by Application, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By End-User, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by Application, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By End-User, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by Application, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By End-User, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by Application, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By End-User, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by Application, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By End-User, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by Application, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By End-User, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by Application, 2021 - 2030 (USD Million) 12.4.4.3. Rest of the Latin America 12.4.4.3.1. Rest of the Latin America market, By End-User, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 Luminex Corporation 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Product Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Illumina Inc 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Product Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. Bio-Rad Laboratories, Inc. 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Product Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Qiagen N.V. 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Product Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Thermo Fisher Scientific Inc 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Product Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. Abcam plc 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Product Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. Merck KGaA 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Product Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Agilent Technologies, Inc. 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Product Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. Becton, Dickinson, and Company 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Product Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Meso Scale Diagnostics 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Product Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. Randox Laboratories 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Product Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Quanterix 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Product Portfolio Analysis 13.12.4. Business Strategy & Recent Development 13.13. Bio-Techne Corporation 13.13.1. Company overview 13.13.2. Financial performance 13.13.3. Product Portfolio Analysis 13.13.4. Business Strategy & Recent Development 13.14. Olink 13.14.1. Company overview 13.14.2. Financial performance 13.14.3. Product Portfolio Analysis 13.14.4. Business Strategy & Recent Development 13.15. DiaSorin S.p.A. 13.15.1. Company overview 13.15.2. Financial performance 13.15.3. Product Portfolio Analysis 13.15.4. Business Strategy & Recent Development 13.16. Seegene 13.16.1. Company overview 13.16.2. Financial performance 13.16.3. Product Portfolio Analysis 13.16.4. Business Strategy & Recent Development 13.17. Promega Corporation 13.17.1. Company overview 13.17.2. Financial performance 13.17.3. Product Portfolio Analysis 13.17.4. Business Strategy & Recent Development 13.18. Siemens Healthineers 13.18.1. Company overview 13.18.2. Financial performance 13.18.3. Product Portfolio Analysis 13.18.4. Business Strategy & Recent Development 13.19. PerkinElmer Inc. 13.19.1. Company overview 13.19.2. Financial performance 13.19.3. Product Portfolio Analysis 13.19.4. Business Strategy & Recent Development 13.20. Shimadzu Biotech 13.20.1. Company overview 13.20.2. Financial performance 13.20.3. Product Portfolio Analysis 13.20.4. Business Strategy & Recent Development 13.21. Antigenix America, Inc. 13.21.1. Company overview 13.21.2. Financial performance 13.21.3. Product Portfolio Analysis 13.21.4. Business Strategy & Recent Development 13.22. Enzo Life Sciences, Inc. 13.22.1. Company overview 13.22.2. Financial performance 13.22.3. Product Portfolio Analysis 13.22.4. Business Strategy & Recent Development 13.23. Boster Biological Technology 13.23.1. Company overview 13.23.2. Financial performance 13.23.3. Product Portfolio Analysis 13.23.4. Business Strategy & Recent Development 13.24. AYOXXA Biosystems GmbH 13.24.1. Company overview 13.24.2. Financial performance 13.24.3. Product Portfolio Analysis 13.24.4. Business Strategy & Recent Development 13.25. Cayman Chemical Company 13.25.1. Company overview 13.25.2. Financial performance 13.25.3. Product Portfolio Analysis 13.25.4. Business Strategy & Recent Development List of Tables (86 Tables) TABLE 1. MARKET, By Product and Service, 2021-2030 (USD Million) TABLE 2. MARKET FOR Instruments, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Consumables, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Software and Services, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET, By Technology, 2021-2030 (USD Million) TABLE 6. MARKET FOR Fluorescence Detection, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Luminescence, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Flow Cytometry, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Multiplex Real-Time PCR, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, By Type, 2021-2030 (USD Million) TABLE 12. MARKET FOR Nucleic Acid, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Protein, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Cell-Based, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By End-User, 2021-2030 (USD Million) TABLE 16. MARKET FOR Hospitals & Research Institutes, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Pharmaceutical & Biotechnology Companies, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Reference Laboratories, BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Research & Development, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET FOR Clinical Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 23. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 25. NORTH AMERICA MARKET, BY Applications, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, By End-User, 2021-2030 (USD Million) TABLE 27. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 28. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 29. EUROPE MARKET, By End-User, 2021-2030 (USD Million) TABLE 30. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. ASIA-PACIFIC MARKET, By End-User, 2021-2030 (USD Million) TABLE 33. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 34. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 35. LAMEA MARKET, By End-User, 2021-2030 (USD Million) TABLE 36. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 37. Luminex Corporation: COMPANY SNAPSHOT TABLE 38. Luminex Corporation: OPERATING SEGMENTS TABLE 39. Illumina Inc: COMPANY SNAPSHOT TABLE 40. Illumina Inc: OPERATING SEGMENTS TABLE 41. Bio-Rad Laboratories, Inc: COMPANY SNAPSHOT TABLE 42. Bio-Rad Laboratories, Inc: OPERATING SEGMENTS TABLE 43. Qiagen N.V.: COMPANY SNAPSHOT TABLE 44. Qiagen N.V.: OPERATING SEGMENTS TABLE 45. Thermo Fisher Scientific Inc: COMPANY SNAPSHOT TABLE 46. Thermo Fisher Scientific Inc: OPERATING SEGMENTS TABLE 47. Abcam plc: COMPANY SNAPSHOT TABLE 48. Abcam plc: OPERATING SEGMENTS TABLE 49. Merck KGaA: COMPANY SNAPSHOT TABLE 50. Merck KGaA: OPERATING SEGMENTS TABLE 51. Agilent Technologies, Inc: COMPANY SNAPSHOT TABLE 52. Agilent Technologies, Inc: OPERATING SEGMENTS TABLE 53. Becton, Dickinson, and Company: COMPANY SNAPSHOT TABLE 54. Becton, Dickinson, and Company: OPERATING SEGMENTS TABLE 55. Meso Scale Diagnostics: COMPANY SNAPSHOT TABLE 56. Meso Scale Diagnostics: OPERATING SEGMENTS TABLE 57. Randox Laboratories: COMPANY SNAPSHOT TABLE 58. Randox Laboratories: OPERATING SEGMENTS TABLE 59. Quanterix: COMPANY SNAPSHOT TABLE 60. Quanterix: OPERATING SEGMENTS TABLE 61. Bio-Techne Corporation: COMPANY SNAPSHOT TABLE 62. Bio-Techne Corporation: OPERATING SEGMENTS TABLE 63. Olink: COMPANY SNAPSHOT TABLE 64. Olink: OPERATING SEGMENTS TABLE 65. DiaSorin S.p.A.: COMPANY SNAPSHOT TABLE 66. DiaSorin S.p.A.: OPERATING SEGMENTS TABLE 67. Seegene: COMPANY SNAPSHOT TABLE 68. Seegene: OPERATING SEGMENTS TABLE 69. Promega Corporation: COMPANY SNAPSHOT TABLE 70. Promega Corporation: OPERATING SEGMENTS TABLE 71. Siemens Healthineers: COMPANY SNAPSHOT TABLE 72. Siemens Healthineers: OPERATING SEGMENTS TABLE 73. PerkinElmer Inc: COMPANY SNAPSHOT TABLE 74. PerkinElmer Inc: OPERATING SEGMENTS TABLE 75. Shimadzu Biotech: COMPANY SNAPSHOT TABLE 76. Shimadzu Biotech: OPERATING SEGMENTS TABLE 77. Antigenix America, Inc: COMPANY SNAPSHOT TABLE 78. Antigenix America, Inc: OPERATING SEGMENTS TABLE 79. Enzo Life Sciences, Inc: COMPANY SNAPSHOT TABLE 80. Enzo Life Sciences, Inc: OPERATING SEGMENTS TABLE 81. Boster Biological Technology: COMPANY SNAPSHOT TABLE 82. Boster Biological Technology: OPERATING SEGMENTS TABLE 83. AYOXXA Biosystems GmbH: COMPANY SNAPSHOT TABLE 84. AYOXXA Biosystems GmbH: OPERATING SEGMENTS TABLE 85. Cayman Chemical Company: COMPANY SNAPSHOT TABLE 86. Cayman Chemical Company: OPERATING SEGMENTS List of Figures (26 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Application-Based Estimation Figure 6 Top 25 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Multiplex Assays, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Multiplex Assays, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Product and Service, 2019 vs. 2025 (USD Million) Figure 12 Market, By Technology, 2019 vs. 2025 (USD Million) Figure 13 Market, By Type, 2019 vs. 2025 (USD Million) Figure 14 Market, By End-User, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Application Type, 2019 vs. 2025 Figure 16 Geographical Snapshot of the Market Figure 17 Consumables to Witness Higher CAGR in Market for Product and Service Segment during Forecast Period. Figure 18 Flow Cytometry to Witness Higher CAGR in Market for Technology Segment during Forecast Period. Figure 19 Protein to Witness Higher CAGR in Market for Type Segment during Forecast Period. Figure 20 Pharmaceutical & Biotechnology Companies to Witness Higher CAGR in Market for End-User Segment during Forecast Period. Figure 21 Research & Development to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview